$MDT

Simply Wall St reports Medtronic (MDT) faces renewed scrutiny after a federal jury ordered it to pay $88 million in compensatory damages over hernia mesh products from its Covidien unit. Medtronic says it plans to challenge the verdict. The article cites MDT shares up 4.72% over 7 days and 18.04% over 90 days, with a “fair value” estimate of $90.37 versus a $91.27 close.

A federal jury in Boston ordered Medtronic, via its Covidien unit, to pay $88 million in Patterson v. Covidien. The jury found Covidien’s Symbotex hernia mesh caused injuries and that doctors were not adequately warned. Awards were $77 million to Larry Patterson and $11 million to Tammy. Medtronic plans post-trial motions and possible appeal.

Medtronic said its Stealth AXiS surgical system, integrating planning, navigation and robotic assistance for spine procedures, received FDA clearance in Feb 2026. It later obtained additional 510(k) clearances for cranial and ENT uses. Medtronic also received CE marks in Europe in Apr 2026 for the system and Jun 2026 for ENT.

Simply Wall St says UBS upgraded Medtronic (MDT) to Buy from Neutral after the company reported its strongest annual revenue growth in a decade, led by cardiac and new product launches, and projected organic revenue growth into fiscal 2027. The article cites MDT annual sales of $36.364B and net income of $4.801B and discusses execution and recall risks.

Investing.com reports unusual options activity in Medtronic plc ahead of its Sept. 1 earnings. More than 25,000 contracts traded, with calls far exceeding puts (23,524 calls vs. 2,033 puts). A $100 September 2026 call drew about 18,801 contracts. The article cites EPS forecast of $1.39 and revenue of $9.55B.

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales of $25.31B (+6.6% YoY) and adjusted EPS of $2.90, both above estimates, and raised full-year guidance to a $101.1B midpoint and $11.68 adjusted EPS. Medtronic (MDT) posted its fastest annual revenue growth in a decade, with FY26 revenue $36.4B and adjusted revenue $36.3B. Article compares post-earnings positioning and risks.

Abbott Laboratories (ABT) reported fiscal Q2 2026 results that beat estimates and raised full-year adjusted diluted EPS guidance to $5.45 to $5.60. Diagnostics sales rose 42% to $3.09 billion, and it reaffirmed comparable sales growth of 6.5% to 7.5%. Medtronic (MDT) reported FY2026 revenue of $36.4 billion and its strongest annual growth in 10 years, while noting tariff headwinds.

UBS upgraded Medtronic (NYSE:MDT) to Buy from Neutral, citing a turnaround underway. The article points to Medtronic’s fiscal Q4 revenue of $9.8B (+9.9% reported, +6.6% organic) and FY2026 revenue of $36.4B (+8.4% reported, +5.8% organic). It highlights cardiac ablation growth and platform progress, while noting sustainability remains unproven.

Medtronic (NYSE: MDT) said it expanded the CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, including ventricular tachycardia and PVCs. The Sphere-9 catheter is the first CE-marked dual-energy, all-in-one mapping and ablation catheter for ventricular ablation. The FDA granted Breakthrough Device Designation, and the U.S. Sphere VT pivotal trial is enrolling.

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.